Semliki Forest virus (SFV) represents a promising gene therapy vector for tumor treatment, because it produces high levels of recombinant therapeutic proteins while inducing apoptosis in infected cells. In this study, we constructed a SFV vector expressing murine interferon alpha (IFNa). IFNa displays antitumor activity mainly by enhancing an antitumor immune response, as well as by a direct antiproliferative effect. In spite of the antiviral activity of IFNa, SFV-IFN could be produced in BHK cells at high titers. This vector was able to infect TC-1 cells, a tumor cell line expressing E6 and E7 proteins of human papillomavirus, leading to high production of IFNa both in vitro and in vivo. When injected into subcutaneous TC-1 tumors implanted in mice, SFV-IFN was able to induce an E7-specific cytotoxic T lymphocyte response, and to modify tumor infiltrating immune cells, reducing the percentage of T regulatory cells and activating myeloid cells. As a consequence, SFV-IFN was able to eradicate 58% of established tumors treated 21 days after implantation with long-term tumor-free survival and very low toxicity. SFV-IFN was also able to induce significant antitumor responses in a subcutaneous tumor model of murine colon adenocarcimoma. These data suggest that local production of IFNa by intratumoral injection of recombinant SFV-IFN could represent a potent new strategy to treat tumors in patients.
INTRODUCTION
Interferon alpha (IFNa), a cytokine that belongs to the group of type I IFNs, was first discovered for its antiviral activity 1 but its promising antitumor activity was soon appreciated. 2 IFNa can inhibit tumor growth through diverse mechanisms, which include an antiproliferative activity, as well as the induction of apoptosis in tumor cells. 3, 4 In addition to these direct effects on tumor cells, IFNa also exerts its antitumor activity on stromal cells, and it has been shown to inhibit angiogenesis by suppressing the proliferation and migration of endothelial cells. 5, 6 Most importantly, IFNa has a central role enhancing antitumor immune responses. For this purpose, this cytokine acts on different immune cells implicated in tumor eradication, being able to enhance the trafficking, expansion and lytic activity of NK cells and T lymphocytes. 7, 8 Although these properties make IFNa very attractive for cancer therapy, clinical use of this cytokine is limited by its toxicity. At the immunological level, IFNa has a dual role in the biology of the T lymphocytes, because it favors an enhanced clonal expansion, but also sensitizes these cells to the antigen-induced cell death normally occurring at the end of an immune response. 9 In addition, it can cause myelosuppression and other severe adverse effects that have led to premature discontinuation of treatment in some patients because of severe leukopenia and thrombocytopenia. 10 Gene therapy can maximize the beneficial effects of IFNa by providing higher and sustained intratumoral concentration of this cytokine, while limiting its systemic adverse effects. 11 Several approaches for the delivery of the IFNa gene to tumor cells have been tested including non-viral and viral vectors. [12] [13] [14] [15] [16] In these studies, intratumoral delivery of IFNa has led to potent antitumor effects, which were mediated by the immunostimulatory capacity of this cytokine. 12, 17, 18 Semliki Forest virus (SFV) belongs to the Alphavirus genus, which comprises enveloped viruses carrying a single positive-strand RNA genome of about 12 kb. 19 An expression vector based on SFV has been developed in which the region coding for the viral structural proteins is replaced by the heterologous gene of interest. 20 The SFV vector RNA can be packaged into viral particles (vps) by co-transfecting it into cells together with two helper RNAs coding for the capsid and the envelope proteins, respectively. 21 On infection, the SFV RNA can replicate leading to high expression of the heterologous protein, but these vectors cannot propagate because they lack the genes coding for the viral structural proteins. Alphavirus-based vectors have emerged as a promising tool for cancer gene therapy, as they combine an extraordinarily high expression level with the capacity to induce apoptosis in infected cells. 22 Thus, alphavirus vectors expressing reporter genes 23, 24 or viral structural proteins 25 can mediate antitumor responses. In these models, the expression of low levels of type I IFN synergizes with the induction of apoptosis in tumor cells to trigger the immune response. The antitumor efficacy of alphavirus vectors can be greatly enhanced by engineering them to express cytokines such as interleukin-12 (refs 26-28) or antiangiogenic factors like endostatin. 29 Another alternative to enhance the antitumor activity of alphavirus vectors is the expression of tumor-associated antigens. SFV expressing E6 and E7 proteins from human papillomavirus (HPV) has been proven to be able to eradicate established TC-1 tumors, a murine epithelial cell line that expresses both E6 and E7 antigens. 30 This tumor model has been widely used to evaluate therapeutic vaccines for HPV-induced cervical carcinomas, one of the most common cancers in women worldwide. In this study, we developed a SFV vector expressing murine IFNa1 (SFV-IFN) and evaluated its antitumor effects in the TC-1 tumor model. As alphaviruses are strongly inhibited by type I IFN responses, 31, 32 the in vitro production and the in vivo efficacy of a recombinant alphavirus vector expressing IFNa represented a technical challenge. In spite of this, we show that SFVIFNa can be produced to normal titers, and can infect the TC-1 cell line and produce IFNa. In vivo, SFV-IFN expressed higher levels of IFNa than a control SFV vector expressing b-galactosidase (b-gal) (SFV-LacZ). Additionally, we also show that SFV-IFN elicited potent antitumor responses, which were not achieved with the control SFV vector. Thus, overexpression of IFNa can enhance the antitumor capacity of SFV vectors.
RESULTS

Construction and characterization of SFV vectors expressing IFNa
To produce SFV-IFN, murine IFNa1 gene was cloned into the SFV vector under the control of the viral subgenomic promoter and using a translation enhancer, as described in Materials and Methods section. As expression of IFNa could affect the production and infectivity of this vector, we first evaluated these parameters in comparison with SFV vectors expressing reporter genes. SFV-IFN vps were produced in BHK cells at high levels with a mean titer of 1.52Â10 10 vp ml -1 , which was similar to the mean titers obtained with vectors like SFV-LacZ or SFV expressing luciferase (SFV-Luc), from which 2.15Â10 10 vp ml -1 and 1.87Â10 10 vp ml -1 were obtained, respectively. SFV-IFN infected hamster BHK cells very efficiently, and could also infect at lower efficiency murine cell lines like L929 fibroblasts, a cell line widely used to detect mouse IFNa activity, and TC-1 epithelial cells, which express HPV E6 and E7 genes ( Figure 1a) . However, the lower efficiency of infection observed in murine cell lines was also observed with SFV-LacZ, indicating that it was not related to IFNa expression. The level of vector RNA replication in infected cells was also measured by quantifying the amount of SFV genomes by real-time reverse transcriptase-PCR. As shown in Figure 1b , the replication of SFV-IFN in all tested cell lines was within the range of the replication of SFVLacZ, used as control. The level of heterologous protein expression was also analyzed in infected cells. In cells infected with SFV-LacZ, the production of b-gal per cell followed a pattern that resembled the observed infectivity, BHK being the cell line that produced higher levels of recombinant protein (Figure 1e ). IFNa was readily detected in the supernatants of all cells infected with SFV-IFN by measuring its capacity to protect L929 cells against the cytopathic activity of encephalomyocarditis virus (Figures 1c and d) . The IFNa levels per cell were similar in L929 and TC-1 cells and lower in BHK (Figure 1f ). In contrast, infection with the control vector induced relatively low amounts of endogenous IFNa in L929 cells, but not in TC-1 or BHK cells (Figures 1c and f) . Thus, TC-1 cells do not produce endogenous IFNa on SFV infection but can produce a high amount of this recombinant protein when infected with SFV-IFN.
In vivo expression of IFNa after intratumoral injection of TC-1 tumors with SFV vectors After confirming that TC-1 cells could be infected in vitro by SFV vectors, we assessed if these vectors could also infect established TC-1 tumors in vivo. For that purpose, 5Â10 8 vp of SFV-Luc were injected into subcutaneous TC-1 tumors implanted in syngeneic mice, and the level of luciferase expression was measured in live animals every 2 days starting on day 1. Luciferase activity was clearly detected in all injected tumors, reaching a maximum at day 1 and decreasing along time until day 9 (Figures 2a and b) . In order to determine if the SFV vector was able to disseminate from the tumor to other organs, luciferase expression was measured in homogenates of different tissues collected at 24 h post inoculation (Figure 2c ). Luciferase expression was at least 10-fold higher in tumors compared with other organs. However, the fact that luciferase was also detected in the skin close to the tumor, heart, spleen, and, to a lesser extent kidney and liver, indicates a certain degree of vector dissemination. This could be due to a high vascularization of tumors and, in fact, subcutaneous injection of the same amount of vector led to much lower luciferase expression in other organs. In animals injected intratumorally with 5Â10 8 vp of SFV-IFN, IFNa expression was detected in both tumors (18.6 ± 11.5 pg mg -1 protein) and sera (899.3 ± 326 pg ml -1 ) at 24h after injection. However, no IFNa was detected in tumors inoculated with SFV-LacZ, in spite of the high sensitivity of the IFNa bioassay that was used. In contrast, mice injected with this control vector presented detectable IFNa in serum at day 1 (95.9 ± 59.4 pg mg -1 protein), although at levels that were 10-fold lower than those produced by SFV-IFN (IFNa levels are expressed as mean ± s.e.m.).
Antitumor efficacy of SFV-IFNa in the TC-1 tumor model
To evaluate the antitumor efficacy of the SFV vector expressing IFNa, we established subcutaneous TC-1 tumors in C57BL/6 mice and treated them at days 21 and 27 after tumor inoculation with 5Â10 8 vp of SFV-IFN. Control animals were inoculated at the same times with 5Â10 8 vp of SFV-LacZ, or phosphate-buffered saline (PBS). We evaluated the efficacy of the treatment by measuring tumor size every 3-4 days. Tumor growth was not affected by the intratumoral injection of SFV-LacZ (Figures 3a and b) . In contrast, SFV-IFN delayed tumor growth in all treated mice, inducing complete tumor eradication in 58% of animals ( Figure 3c ). This therapeutic effect was reflected in a significant increase in the survival of mice that received SFV-IFN, compared with control groups (Figure 3d ). Thus, the apoptosis induced by SFV in this established model is not enough to induce tumor regression, being the overexpression of IFNa provided by SFV-IFN necessary to trigger a curative response.
Antitumor efficacy of SFV-IFNa in the MC38 tumor model
In order to determine whether SFV-IFN could be used as a general method for tumor therapy, subcutaneous MC38 tumors were established in C57BL/6 mice and treated at days 11 and 18 after tumor inoculation with 5Â10 8 vp of SFV-IFN. Control mice were inoculated with saline. The efficacy of treatment was evaluated by measuring the size of tumor nodules every 3-4 days. In this model, SFV-IFN delayed tumor growth in most treated mice, although complete tumor eradication was achieved in only 25% of animals ( Figure 4a ). A significant increase in the survival of mice that received SFV-IFN, compared with the control group was also observed (Figure 4b ).
Characterization of the cellular immune response involved in the antitumor effect mediated by SFV-IFN
Antitumor responses induced by IFNa-expressing vectors have been reported to be mediated by the induction of a strong cellular immune response against the tumor. We investigated whether treatment of TC-1 tumors with SFV-IFN could induce a T-cell response against an immunodominant epitope of HPV E7. This antigen is expressed by TC-1 cells and could be released on infection with SFV vectors. We performed an in vivo killing assay in mice bearing TC-1 tumors 7 days after SFV-LacZ or SFV-IFN intratumoral administration. SFV-IFN greatly increased the killing of splenocytes bearing the E7 epitope, indicating that an E7-specific T-cell response was established on SFV-IFN inoculation (Figure 5a ). To gain deeper insight into the generated immune response, we analyzed two important immunosuppressive populations present in the tumor stroma. Myeloid suppressor cells experienced a marked increase in the levels of Ly6C in SFV-IFN-treated mice (Figure 5b ). This surface marker can be activated by IFNa and these cells will selectively populate sites of experimentally induced inflammation. 33 Moreover, it has been shown to be a requirement for successful immunotherapy in other tumor models. 34 In addition, a decrease in the fraction of T regulatory cells within the total CD4 + T-cell population was observed specifically in the SFV-IFN group (Figure 5c ). All these immunological events led to the development of an immunological memory, since all mice that rejected tumors were protected against a second challenge with TC-1 cells (data not shown). Therefore, SFV-IFN can generate strong tumor-specific T-cell responses without expressing any viral antigen.
To confirm that the E7-specific cytotoxic response was indeed responsible for tumor eradication, we depleted CD8 + cells before virus administration. This maneuver totally abrogated the antitumor effect of SFV-IFN. In contrast, CD4 + cell depletion only led to a partial reduction of the therapeutic effect (Figure 6a) .
Finally, we analyzed whether intratumoral administration of recombinant IFNa (rIFNa) could replace the expression of this cytokine by SFV. For this study, we used doses of rIFNa similar to the ones expressed by SFV-IFN within tumors. Neither rIFNa nor SFV-LacZ alone were able to induce eradication of tumors, but simultaneous intratumoral administration of SFV-LacZ and rIFNa was able to restore the antitumor efficacy (Figure 6b ). Therefore, SFV induction of endogenous type I IFNs in tumors is not sufficient to initiate an immune response against tumor cells, while complementation with rIFNa or virus-expressed IFNa can maximize the SFV antitumor activity.
Lack of hematological toxicity after intratumoral injection of SFV-IFN Diffusion of IFNa from the tumor to the periphery could lead to systemic adverse effects. Alterations in the hematopoietic system, mainly thrombocytopenia and leukopenia, are among the most important unwanted consequences of IFNa-based therapies. To test whether treatment with SFV-IFN could induce this type of toxicity, we evaluated in tumor-bearing mice the kinetics of white blood cells and platelets counts at day 1, 3 and 9 after vector administration. No significant change was observed in the number of platelets after treatment (data not shown). The only effect that could be detected was a drop of approximately 69.5 and 33% in white blood cells count 24 h after intratumoral injection of SFV-IFN or SFV-LacZ, respectively. As these cells recovered completely at day 3, this sharp drop, which was significantly higher in SFV-IFN-treated animals (Po0.05), may reflect the IFNa-induced inhibition of lymphocyte egress from lymphoid organs, 35 rather than a real toxic effect as described with other IFNa-based gene therapies. Thus, SFV-IFN can achieve a strong antitumor efficacy without inducing systemic hematological toxicity.
DISCUSSION
In this paper, we report the production and evaluation of the therapeutic potential of a SFV vector expressing IFNa in established tumor models in immunocompetent mice. To date, no alphavirus vector expressing IFN has been reported, which could be due to concerns argued against expression of this type of antiviral cytokine from a self-replicating RNA vector. Alphaviruses are very sensitive to the action of type I IFNs, and it would be reasonable to think that expression of these cytokines from such a recombinant vector could hinder its production and activity. 31, 32 On the other hand, alphaviruses induce the release of type I IFNs in infected cells and expression of more IFNa from the vector may be redundant for therapeutic purposes. 31, 32, 36 In spite of these potential drawbacks, we have shown that it is possible to produce high titers of recombinant SFV vectors expressing IFNa in BHK cells. The most likely explanation for achieving this high SFV-IFN production is the fact that BHK cells have been shown to be defective in type I IFN responses. It has been reported that BHK cells do not produce IFN on infection with an RNA virus like Newcastle disease virus. 37 In addition, BHK cells can support the replication of noncytopathic alphavirus RNA mutant replicons, in contrast to cell lines with an intact type I IFN response where those replicons are rapidly lost. [38] [39] [40] Not only is the production of SFV-IFN feasible but IFNa expression could also be achieved in infected cells independently of endogenous type I responses. We have observed that on infection with SFV-IFN, similar levels of IFNa are expressed in TC-1 and L929 cells, in spite of the fact that TC-1, the main tumor target cells used in our study did not seem to develop a type I IFN response after infection with SFV-LacZ control virus (Figure 1f) . Thus, this cell line provides us with a tumor model that has lost the ability to produce IFNa. This constitutes a mechanism of resistance developed by many tumors, because this cytokine has shown to be able to inhibit proliferation of cancer cells. Interestingly, when TC-1 tumors were treated with SFVLacZ in vivo, we could detect IFNa activity in sera. This low IFNa expression was probably due to the infection of non-tumor cells and was not enough to retard tumor growth. The fact that L929 cells can support SFV-IFN replication in spite of being sensitive to IFNa is probably due to the strong shut-off of host-cell protein synthesis induced by SFV at early times after infection. It has been reported that this shut-off affects many proteins involved in the IFN response, a mechanism developed by alphaviruses to escape antiviral innate responses. 38 This virus-induced type I IFN response can synergize with other cytokines or tumor antigens expressed from the SFV vector, resulting in good antitumor responses. 27, 28, 41 However, we have shown that overexpression of IFNa from SFV in the absence of other therapeutic transgenes is non-redundant and, moreover, essential to achieve a therapeutic antitumor activity. These results were supported by the fact that co-injection of SFV-LacZ with rIFNa was able to induce a similar level of antitumor activity than SFV-IFN.
A great interest in IFNa gene delivery for cancer therapy has arisen since the pioneer work using stable transfected tumor cells. 14 Recently, two approaches have been gaining importance in this field, both of which are reflected in our therapeutic strategy: tumor-targeted expression and simultaneous lysis of tumor cells. As an example of the first approach, De Palma et al. 13 achieved expression of IFNa in tumor vessels, resulting in a strong antitumor response with no toxicity. Our strategy was able to release a maximal amount of IFNa in the tumor although the cytokine could also be detected systemically. This could be due to IFN release from tumor nodules, but probably also to infection of other tissues because of vector escape, as it was observed with the SFV-Luc vector (Figure 2c ). However, systemic IFNa levels were low and virtually no hematological toxicity was detected in treated animals, demonstrating a good safety level for this therapeutic approach.
The second important approach is the combination of tumor lysis by a cytolytic virus with the simultaneous release of high levels of type I IFN. The induction of apoptosis by the vector can lead to the release of tumor antigens that can be taken up by antigen-presenting cells contributing to the development of antitumor immune responses, which in this case will be boosted by the high IFNa expression. 42 Several studies have demonstrated that this combined approach is extremely promising, since it could represent a new generation of IFNa-based gene therapy. 11, 43, 44 In this study, we show that SFV-IFN is able to remodel tumor infiltrating myeloidderived suppressor cells and to alter the equilibrium in the tumor stroma between helper and regulatory T cells. These events pave the way to the processing of tumor-derived antigens by antigen-presenting cells, leading to an efficient cytotoxic T lymphocyte antitumor Figure 6 Requirements for SFV-IFN antitumor activity. Six groups of C57BL/6 mice (n¼5) were injected with 5Â10 5 TC-1 cells on day 0 and then on days 21 and 27 they received intratumorally 5Â10 8 vp of SFV-IFN (a), or the same dose of SFV-LacZ, 2500 U of rIFNa or SFV-LacZ in combination with 2500 U of rIFNa (b). Depletions of CD4 + or CD8 + cells were performed in two of the SFV-IFN groups by intraperitoneal injection of 300 mg of specific antibodies administered at days À2 and À1 before virus injection (a). Each curve represents the evolution of the mean tumor diameter for each individual mouse. The numbers in the right upper corner of each graph indicate the number of tumor-free mice on day 110 relative to the total number of animals in each group, and the percentage of complete tumor regressions, respectively. Each group was compared with the SFV-IFN-treated group with the log-rank test and the P-value is shown. Mice were killed when the tumor diameter reached 15 mm or when necessary because of the health status of the animals.
response without the requirement of expressing tumor-associated antigens by the vector. In particular, the results obtained with the TC-1 model suggest that SFV-IFN could represent a potent new strategy for treatment of HPV-associated tumors. However, the fact that SFV-IFN was also able to induce antitumor responses in the nonrelated MC38 tumor model suggests that this strategy could have a wider applicability.
In conclusion, the SFV-IFN vector developed in this research can be considered as a safe and attractive new alternative to the use of other oncolytic vectors that have been tested for cancer treatment.
MATERIALS AND METHODS
Construction of SFV-IFN vectors
Plasmid pSFVb1-2A has been previously described and was kindly provided by Dr P Liljeström (Karolinska Institute, Stockholm, Sweden). 20, 21, 45 pSFV-Luc 27 and pCMV-IFNa 46 were generated in our laboratory and have also been described. To construct pSFV-IFN, XmaI restriction sites were inserted flanking the IFNa1 sequence (devoid of the initial ATG) by PCR using the following primers: forward 5¢-CCCGGGGCTAGGCTCTGTGCTTTCC-3¢ and reverse 5¢-CCCGGGTCATTTCTCTTCTCTCAGTCTTC-3¢. The PCR product was cloned into the vector pcDNA3.1/V5-His TOPO TA (Invitrogen, Carlsbad, CA, USA). The XmaI fragment obtained after digestion of the previous plasmid was inserted into the XmaI site in pSFVb1-2A in frame with the minimal SFV capsid translation enhancer (b1), using the 2A autoprotease from foot and mouth disease virus as a linker. Plasmid pSFV-LacZ was constructed in a similar way by inserting into pSFV-b1-2A a PCR fragment containing the LacZ gene in frame with the b1 SFV capsid translation enhancer, using the 2A autoprotease from foot and mouth disease virus as a linker (details available on request).
Animals and cell lines
Pathogen-free 5-week-old female C57BL/6 mice were purchased from Harlan Laboratories (Barcelona, Spain), housed in appropriate animal care facilities during the experimental period, and handled following the international guidelines required for experimentation with animals.
BHK-21 cells, the cells needed for SFV production, were cultured as described. 20 TC-1 tumor cells expressing HPV16-E6 and HPV16-E7 proteins are derived from primary mouse epithelial cells, and were obtained from ATCC (LGC Promochem, Molsheim, France). MC38 murine adenocarcinoma cells 27 and TC-1 cells were maintained in RPMI 1640 with GlutaMAX supplemented with 10% heat-inactivated fetal calf serum, 100 units ml -1 penicillin, 100 mg ml -1 streptomycin, 0.4 mg ml -1 geneticin (only for TC-1 cells) and 5Â10 À5 mol l -1 2-mercaptoethanol (Life Technologies, Cergy-Pontoise, France). L929 cells (ATCC, Manassas, VA, USA) were cultured in Dulbecco's modified Eagle's medium supplemented with 10% fetal calf serum, 2 mM L-glutamine, 100 U ml -1 streptomycin and 100 mg ml -1 penicillin.
Transfection of cells and virus production
RNA synthesis and transfection into BHK-21 cells by electroporation was performed as described previously. 47 Packaging of recombinant RNA into SFV vp was performed by co-electroporation of BHK-21 cells with the recombinant RNA and both helper-S2 and helper-C-S219A SFV RNAs as described. 21 SFV particles were purified by ultracentrifugation as described previously. 48 Indirect immunofluorescence of infected BHK-21 cells was performed to determine the titer of recombinant virus stocks. 49 A rabbit polyclonal antiserum specific for the nsp2 subunit of SFV replicase was used as primary antibody. 39 Analysis of SFV infectivity, replication and expression in vitro BHK-21, L929 or TC1 cell lines were infected in six-well plates with serial dilutions of SFV-LacZ or SFV-IFN vp. After 24 h, infectivity was measured by indirect immunofluorescence against SFV replicase as described above. The dilution of viruses that allowed a precise quantification of infected cells was used in the following experiments. To determine the RNA replication levels, cells were infected in six-well plates and 24 h later RNA was isolated with Trizol (Invitrogen) following the manufacturer's instructions. RNA was treated with DNase I and retrotranscribed to complementary DNA with reverse transcriptase from the Moloney murine leukemia virus in the presence of RNase OUT (all the reagents were from Invitrogen). The reaction was incubated for 1 h at 37 1C, denatured for 1 min at 95 1C and cooled to 4 1C. Samples were used immediately for PCR or stored at À20 1C. Two specific primers were used to amplify a 200-bp fragment of SFV replicase: SF-1699-RS 5¢-GAGGTGTTTCCA CGACCC-3¢ (reverse) and SF-1534-VS 5¢-CTGTTCTCGACGCGTCGTC-3¢ (forward). A standard curve was performed with a plasmid bearing the amplified fragment. All reagents were from Bio-Rad (Hercules, CA, USA). Data are represented as the amount of viral genome copies per infected cell normalized to the levels of SFV-LacZ in BHK.
The amount of b-gal present in cell lysates 24 h after infection was measured by an enzymatic reaction as described previously. 47 For titration of SFV-LacZ infected cells from duplicate dishes were stained with 5-bromo-4-chloro-3-indolyl-b-D-galactopyranoside (X-Gal) (Invitrogen). The amount of IFNa in the supernatant 24 h after infection was quantified by a cytopathic effect reduction assay as described below. The amount of b-gal or IFNa produced per cell was calculated by dividing the amount of protein detected per dish by the number of infected cells in each dish.
Induction, infection and treatment of TC-1 and MC38 tumors C57BL/6 female mice were subcutaneously injected with 5Â10 5 TC-1 or MC38 cells resuspended in 100 ml of PBS. On days 21 and 27 after TC-1 tumor inoculation, 5Â10 8 vp of SFV-IFN, SFV-LacZ, SFV-LacZ plus 2500 U of rIFNa (Hycult Biotech, Uden, The Netherlands), or 2500 U of rIFNa were resuspended in a total volume of 60 ml of saline buffer and injected intratumorally. Anti-CD8b (clone 53.6.72) and anti-CD4 (clone GK1.5) antibodies (provided by Dr I Melero, Center for Applied Medical Research, Pamplona, Spain) were purified from culture supernatants by affinity chromatography in protein G-sepharose columns, according to the manufacturer's instructions (GE Healthcare Biosciences, Uppsala, Sweden), and 300 mg per mice per day were injected intraperitoneally on days À2 and À1 before SFV administration. In the case of MC38, the same doses of SFV-IFN were injected on days 11 and 18 after tumor inoculation. In all cases, tumor growth was monitored every 3-4 days by measuring two perpendicular tumor diameters and considering the average diameter as an indicator of tumor size. For analysis of infectivity with SFV-Luc, tumor-bearing mice were injected intratumorally with 5Â10 8 vp of SFV-Luc. On days 0, 1, 3, 5, 7 and 9, mice were anesthetized and injected intraperitoneally with 100 ml of D-luciferin at 30.3 g ml -1 (Xenogen Corp., Hopkinton, MA, USA). Luciferase activity images were acquired with an IVIS charge-coupled-device camera system (Xenogen Corp.) and analyzed with the LivingImage 2.20 software package (Xenogen Corp.). For analysis of vector dissemination, tumor-bearing mice were injected subcutaneously or intratumorally with 5Â10 8 vp of SFV-Luc or with saline (only intratumorally). Tissues were excised 24 h after vector inoculation, quickly frozen in liquid nitrogen and homogenized in 300-500 ml of lysis buffer (PBS with 0.05% Tween and protease inhibitor cocktail tablets (Complete, Roche, Basel, Switzerland)). After homogenization samples were centrifuged twice 10 min at 13 000 r.p.m. and luciferase activity was measured in the supernatants with a conventional luminometer. The amount of total protein present in each tissue homogenate was quantified by a standard Bradford assay.
White blood cells and platelets counts were determined using Hemavet 950 (Drew Scientific Inc., Dallas, TX, USA) at 0, 1, 3 and 9 days after intratumoral injection of mice bearing subcutaneous TC-1 tumors with 5Â10 8 vp of SFV-LacZ or SFV-IFN.
Measurement of IFNa activity: cytopathic effect reduction assay
To measure in vivo production of IFNa, animals were killed 24 h after virus inoculation and tumors were frozen, homogenized in 300 ml of PBS with protease inhibitor cocktail tablets (Roche) and centrifuged for 5 min at 9300 g. Supernatants were used for cytokine determination. Blood samples from these animals were previously drawn using the retro-orbital route after isofluorane (Abbott, Chicago, IL, USA) anesthesia. Sera were recovered from two consecutive centrifugations at 9.1Âg for 5 min and stored at À20 1C. Supernatants from infected cells were collected after 24 h and used for IFNa determination.
The IFNa activity contained in the different samples were measured by the capacity of serial dilutions of the preparations to protect murine fibroblast L929 cells, (3Â10 4 per microtiter well) against the cytopathic activity of encephalomyocarditis virus after an overnight incubation. When maximum cytopathic effect reduction was achieved in control cells, viable IFN-protected cells were measured by luminometry with the ViaLight Plus Kit (Lonza, Basel, Switzerland). Readings were plotted in a dose-response curve (Prism 5, GraphPad Software, Inc., San Diego, CA, USA). The potency of the antiviral activity was calculated with reference to the dilutions of a standard recombinant rIFNa (PBL, Piscataway, NJ, USA) used in each assay.
In vivo killing assay
Twenty-one days after inoculation of 5Â10 5 TC-1 cells, C57BL/6 mice were intratumorally treated with 5Â10 8 vp of SFV-IFN. Control mice received 5Â10 8 vp of SFV-LacZ. On day 7, splenocytes from naïve mice were extracted. Peptide-pulsed cells were coated with 9 mM E7 49À57 cytotoxic epitope-derived peptide (RAHYNIVTF, Proimmune Ltd, Oxford, UK) and labeled with 2.5 mM carboxyfluorescein succinimidyl ester (CFSE) (Molecular Probes, Eugene, OR, USA). Control irrelevant peptide-pulsed splenocytes were coated with 9 mM b-gal cytotoxic epitope-derived peptide TPHPARIGL and labeled with 0.25 mM CFSE. Splenocytes were transferred intravenously to SFV-treated mice (5Â10 6 cells of each population). On day 8, spleens were isolated and examined by flow cytometry FACSCalibur (BD Biosciences, San Jose, CA, USA). The killing percentage was calculated as: 100À(%CFSE high immunized/%CFSE low immunized)/(%CFSE high control/%CFSE low control).
Tumor immune cell infiltration analysis
Twenty-one days after inoculation of 5Â10 5 TC-1 cells, C57BL/6 mice were intratumorally treated with 5Â10 8 vp of SFV-IFN. Control mice received 5Â10 8 vp of SFV-LacZ. On day 3, animals were killed and tumors were harvested, dissociated mechanically, incubated with 1 mg ml -1 Collagenase D and 50 mg ml -1 DNAse I (Roche) in PBS for 30 min at 37 1C, and filtered through 70-mm cell strainers (BD Biosciences). Staining was performed with fluorochrome-conjugated antibodies specific for the following markers: CD4 (clone RM4-5), CD25 (PC61), CD11b (M1/70), and Ly6C (AL-21). All antibodies and mouse Fc block (2.4G2) were purchased from BD Pharmingen (San Diego, CA, USA). Phycoeritrin-conjugated anti-mouse FoxP3 (FJX-16s) was purchased from eBioscience (San Diego, CA, USA). Intracellular staining of FoxP3 was performed using mouse Regulatory T-cell staining kit (eBioscience) following the manufacturer's instructions. In all, 50 000 events were acquired on a four-color FACSCalibur flow cytometer (BD Biosciences). Flow cytometry data were analyzed using FlowJo software (Tree Star, San Carlos, CA, USA).
Statistical analysis
Monolix software (http://www.monolix.org/) was used for analysis of tumor growth by non-linear mixed effect models. Mean diameters of tumors over time were fitted using the model described previously 50 and treatments were compared using the likelihood ratio test. Prism software (GraphPad Software Inc.) was employed for the rest of statistical analysis. Survival of tumor-bearing animals was represented by Kaplan-Meier plots and analyzed by a log-rank test. T-test was used to compare two experimental groups. P-values o0.05 were considered to be statistically significant.
